Skip to content

Study · Non-randomized trial · 1986

3 results

Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G

Calcified tissue international1 Jan 1986Cited by 124 (Europe PMC)

PMID3079649 (opens in a new tab)DOI10.1007/bf02556587 (opens in a new tab)PepBankPUB-03079649
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, salmon calcitonin significantly increased bone mineral content from baseline.

    In plain wordsIn women with postmenopausal osteoporosis, salmon calcitonin significantly increased bone mineral content from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseBone mineral content
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 MRC units every other day · intramuscular · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment a significant mean increment of BMC and nondialyzable OHPr/creatinine values and a significant decrease of total OHPr/creatinine values were observed in the treated group, while controls showed a significant decrease in BMC values.
    3 context sentences
    Summary · context
    In this paper we present the results of a 12-month double-blind clinical multicenter study assessing the effects of synthetic salmon calcitonin (CT) administration in a group of white postmenopausal osteoporotic women.
    Summary · context
    Treated patients were given 100 MRC units of synthetic salmon CT injected i.m. in the morning every other day.
    Summary · context
    Control patients received a placebo injection.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, salmon calcitonin significantly increased nondialyzable OHPr/creatinine from baseline.

    In plain wordsIn women with postmenopausal osteoporosis, salmon calcitonin significantly increased the nondialyzable hydroxyproline-to-creatinine measure from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseNondialyzable OHPr/creatinine
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 MRC units every other day · intramuscular · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment a significant mean increment of BMC and nondialyzable OHPr/creatinine values and a significant decrease of total OHPr/creatinine values were observed in the treated group, while controls showed a significant decrease in BMC values.
    3 context sentences
    Summary · context
    In this paper we present the results of a 12-month double-blind clinical multicenter study assessing the effects of synthetic salmon calcitonin (CT) administration in a group of white postmenopausal osteoporotic women.
    Summary · context
    Treated patients were given 100 MRC units of synthetic salmon CT injected i.m. in the morning every other day.
    Summary · context
    Control patients received a placebo injection.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, salmon calcitonin significantly decreased total OHPr/creatinine from baseline.

    In plain wordsIn women with postmenopausal osteoporosis, salmon calcitonin significantly lowered the total hydroxyproline-to-creatinine measure from baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseTotal OHPr/creatinine
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 MRC units every other day · intramuscular · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months of treatment a significant mean increment of BMC and nondialyzable OHPr/creatinine values and a significant decrease of total OHPr/creatinine values were observed in the treated group, while controls showed a significant decrease in BMC values.
    3 context sentences
    Summary · context
    In this paper we present the results of a 12-month double-blind clinical multicenter study assessing the effects of synthetic salmon calcitonin (CT) administration in a group of white postmenopausal osteoporotic women.
    Summary · context
    Treated patients were given 100 MRC units of synthetic salmon CT injected i.m. in the morning every other day.
    Summary · context
    Control patients received a placebo injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.